世界のがんペプチドワクチン療法市場及びパイプラインインサイト...市場調査レポートについてご紹介

1. Introduction to Peptide Cancer Therapeutics

2. Mechanism of Peptide Cancer Therapeutics

3. Peptide Cancer Therapeutics Market Outlook
3.1 Market Overview
3.2 Cancer Peptide Clinical Pipeline Overview

4. Peptide Cancer Therapeutics Market Dynamics
4.1 Favorable Growth Parameters
4.2 Key Issues to be Resolved

5. Peptide Cancer Therapeutics Market Future Growth Prospects

6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-0
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-III
7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company

8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country
8.1 No Development Reported
8.2 Discontinued
8.3 Market Withdrawal
8.4 Suspended

9. Competitive Landscape
9.1 AngioChem
9.2 Antigen Express
9.3 Amgen
9.4 GlaxoSmithKline
9.5 Galena Biopharma
9.6 Ipsen
9.7 Merck & Co
9.8 PeptiDream
9.9 Roche
9.10 Sanofi

Figure 1-1: Use of Peptides in Various Ailments
Figure 2-1: Mode of Action of Peptide Cancer Therapeutics
Figure 2-2: Targeted Peptide Cancer Therapeutics Development
Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018
Figure 3-2: Global Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-3: Global Peptide Cancer Drug Pipeline by Phase (Number), 2014
Figure 3-4: No Development Reported in Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-5: No Development Reported in Peptide Cancer Drug Pipeline by Phase (Number), 2014
Figure 3-6: Discontinued Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-7: Discontinued Peptide Cancer Drug Pipeline by Phase (Number), 2014
Figure 3-8: Suspended Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-9: Suspended Peptide Cancer Drug Pipeline by Phase (Number), 2014